Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase...
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada’s operational growth - BOSTON, Jan. 03,...
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second...
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company – – Expanded the Company’s...
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 12, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada...
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
- In its inaugural year, DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to combat disparity and support people living with Duchenne - - Announced in...
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...